Geneva, May 29 -- International Clinical Trials Registry received information related to the study (ChiCTR2600124979) titled 'Clinical Studies of the DLL3-Targeted Imaging Agent (DLL3I) in Small Cell Lung Cancer' on May 20.

Study Type: Diagnostic test

Study Design: Cross-sectional

Primary Sponsor: Huashan Hospital, Fudan University

Condition: Small Cell Lung Cancer

Intervention: Gold Standard:Tumor Histopathology

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-05-30

Target Sample Size: Target condition:10;Difficult condition:0

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=323991

Published by HT Digital Content Services with permission from H...